Sato Pharmaceutical Co., Ltd.
Privately held: no public share price · Japan
Assets
(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
berdazimer(Zelsuvmi) | Approved | Nitric oxide releaseSmall molecule | Molluscum Contagiosum |
| Approved | PDE4Small molecule | PsoriasisSeborrheic Dermatitis | |
| Approved | PDE4Small molecule | Atopic DermatitisPsoriasis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
April 2028 (1)
Est. primary completion 2028-04-27 · NCT07916480 · CT.gov ↗
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
23 February 2027FDA action dateRoflumilast (Zoryve)PDUFA target date 23 Feb 2027 for Zoryve cream 0.05% in infant AD
US, FDA · Source ↗
Recent
8 July 2026Filing acceptedRoflumilast (Zoryve)FDA accepts sNDA for Zoryve cream 0.05% in infant atopic dermatitis
US, FDA · Source ↗
29 June 2026ApprovalRoflumilast (Zoryve)FDA approves ZORYVE cream 0.3% for plaque psoriasis in children as young as 2
US, FDA · Source ↗
Financial reports
No financial reports recorded.